DOD awards $78M to 5 med tech companies; NeuroSigma postpones $50M IPO;

@FierceMedDev: Histogenics files for IPO, as Autogenomics refiles again. Article | Follow @FierceMedDev

@VarunSaxena2: HillaryClinton says we have to review +s and -s of device tax. An expected non-answer. | Follow @VarunSaxena2

@EmilyWFierce: Third time's a charm? FDA panel recommends Boston Scientific's Watchman device by a slim margin. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in #cancer cells. More | Follow @MichaelGFierce

> Becton Dickinson ($BDX) failed in its bid to overturn a $113.5 million antitrust verdict in favor Retractable Technologies ($RVP) overturned. The case was reviewed by Texas federal judge and regards safety syringe technology. Story

> The U.S. Department of Defense awarded a total of $78 million to med tech companies including Aethlon Medical, InfraScan, 3M, CAE Healthcare and Spacelabs Medical. More

> The women's healthcare unit of The Cooper Companies ($COO) acquired disposable hysteroscope maker EndoSee for $44 million. Release

> NeuroSigma postponed its IPO to raise $50 million, which was slated for yesterday, citing poor market conditions. The neuromodulation company has a device for drug-resistant epilepsy and depression. Release

Biotech News

@FierceBiotech: VC giant NEA recruits a biotech vet to join its ranks of dealmakers. Report | Follow @FierceBiotech

@JohnCFierce: Biotechs tap a swelling tide of investment cash to fund growing R&D ops--or, laissez les bon temps rouler. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. Release | Follow @DamianFierce

@EmilyMFierce: Ebola genome browser launched to aid drug discovery. FierceBiotech Research story | Follow @EmilyMFierce

> Auxilium takes money, runs from inversion with $2.6B Endo deal. Report

> Shire's long-delayed ADHD drug hits another FDA speed bump. Article

Pharma News

@FiercePharma: Top-read in FP Weds: Novartis, GSK shake up executive ranks as overhaul continues. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI, this week's issue of FiercePharmaMarketing is here. And you can subscribe here. | Follow @CarlyHFierce

> Merck can't sidestep $250M gender-bias suit, judge says. Story

> Auxilium dumps QLT inversion deal for $2.6B Endo buyout. Article

Vaccines News

> Pfizer's meningitis B vaccine is effective when given with HPV jab. More

> Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant. Story

> Biotechs angling for T-cell response in race for next-gen herpes vaccine. Article

> Takeda appoints new vax development head as Novartis' Oswald heads for the door. Report

> Could 'space bacteria' help create vaccines? Item

Pharma Manufacturing News

> Impax says $700M deal for Tower will help it deal with quality issues. More

> Hospira recalls drug because of storage glitch during shipping. Report

> France's Ceva has completed a sterile facility for vet drugs. Item

> Gerresheimer adjusts earnings forecast lower in wake of FDA crackdown. Article

> CSL announces $450M commitment to expand two of its plants. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.